GENENTECH, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03361137
- Locations
- ๐บ๐ธ
Childrens Hospital of LA, Los Angeles, California, United States
๐บ๐ธIndiana Hemophilia & Thrombosis center, Indianapolis, Indiana, United States
๐บ๐ธNewark Beth Israel Medical Center, Newark, New Jersey, United States
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT03341884
- Locations
- ๐บ๐ธ
American Research Corporation Inc., San Antonio, Texas, United States
๐บ๐ธClinical Pharmacology of Miami, Inc., Miami, Florida, United States
๐บ๐ธNew Orleans Center for Clinical Research, Knoxville, Tennessee, United States
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT03332797
- Locations
- ๐ช๐ธ
Hospital Quiron Barcelona, Barcelona, Spain
๐ช๐ธHospital Universitari Vall d'Hebron, Barcelona, Spain
๐ช๐ธHospital General Universitario Gregorio Maranon, Madrid, Spain
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03298516
- Locations
- ๐บ๐ธ
Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749, New York, New York, United States
๐จ๐ฆJewish General Hospital / McGill University, Montreal, Quebec, Canada
๐จ๐ฆUniversity of Alberta Hospital, Edmonton, Alberta, Canada
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03295877
- Locations
- ๐บ๐ธ
Retina Specialty Institute, Pensacola, Florida, United States
๐บ๐ธCalifornia Retina Consultants - Santa Maria, Santa Maria, California, United States
๐บ๐ธRetina Consultants of Southern Colorado PC; Clinical Research Department, Colorado Springs, Colorado, United States
A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03290703
- Locations
- ๐ฌ๐ง
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- Conditions
- MelanomaTriple Negative Breast CancerRenal CancerBladder CancerColorectal CancerNon-Small Cell Lung CancerOther Solid CancersHead and Neck Cancer
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT03289962
- Locations
- ๐บ๐ธ
Dana Farber Can Ins, Boston, Massachusetts, United States
๐จ๐ฆThe Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
๐จ๐ฆPrincess Margaret Cancer Center, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 457
- Registration Number
- NCT03289143
- Locations
- ๐ต๐ฑ
M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland
๐ต๐ฑNovo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland
๐ต๐ฑAMED Medical Center, Warszawa, Poland
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT03275103
- Locations
- ๐ช๐ธ
Clinica Universidad de Navarra, Pamplona/iruรฑa, Navarra, Spain
๐ช๐ธHospital Clinico Universitario de Salamanca, Salamanca, Spain
๐จ๐ฆJewish General Hospital, Montreal, Quebec, Canada
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03237741
- Locations
- ๐ฌ๐ง
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom